ALT

Altimmune Inc

Add to Watchlist

Advanced Chart

3.610

-0.08(-2.168%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.715

Open

3.620

VWAP

3.64

Vol

1.80M

Mkt Cap

292.39M

Low

3.580

Amount

6.57M

EV/EBITDA(TTM)

Total Shares

70.90M

149.46M

EV/OCF(TTM)

P/S(TTM)

13.32K

Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

560.00

-88.8%

560.00

-88.8%

560.00

-88.8%

Estimates Revision

The market is revising Downward the revenue expectations for Altimmune, Inc. (ALT) for FY2025, with the revenue forecasts being adjusted by -97.49% over the past three months. During the same period, the stock price has changed by -30.17%.

Revenue Estimates for FY2025

Revise Downward

-97.49%

In Past 3 Month

Stock Price

Go Down

-30.17%

In Past 3 Month

10 Analyst Rating

423.27% Upside

Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 18.89 USD with a low forecast of 1.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

1 Sell

Moderate Buy

423.27% Upside

Current: 3.610

Low

1.00

Averages

18.89

High

28.00

423.27% Upside

Current: 3.610

Low

1.00

Averages

18.89

High

28.00

Goldman Sachs

initiated

2025-07-10

Reason

Goldman Sachs

Price Target

2025-07-10

initiated

Reason

Goldman Sachs resumed coverage of Altimmune with a Sell rating and $1 price target, representing 79% downside. The company's data to-date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or metabolic dysfunction associated steatohepatitis, the analyst tells investors in a research note. The firm sees challenges for Altimmune to execute the full clinical development program required to bring pemvidutide to market.

Citizens JMP

Outperform

NULL

downgrade

$25 -> $15

2025-07-10

Reason

Citizens JMP

Price Target

$25 -> $15

2025-07-10

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Altimmune to $15 from $25 and keeps an Outperform rating on the shares. Pemvidutide is still a competitive MASH candidate, but its path forward has become more difficult, the analyst tells investors in a research note. The firm thinks pemvidutide will hit both fibrosis and MASH resolution in Phase 3, but says Altimmune needs additional capital to get through the pivotal MASH program, which will now be the overhang on the stock.

Jefferies

Buy

maintain

$28

2025-06-27

Reason

Jefferies

Price Target

$28

2025-06-27

maintain

Buy

Reason

Jefferies believes Altimmune stock dropping 50% after the company announced results from its IMPACT study is overkill, as data met the firm's most likely scenario. Jefferies sees pemvidutide as a viable/safe drug uniquely positioned in MASH as the first incretin to hit statistical significance on histology at 24 weeks with potential to deepen with time and thinks these factors differentiate the drug from the fibroblast growth factor 21 class, the firm told investors in a research note. Jefferies added that the company can take meaningful share in the growing MASH market if successful. The firm reiterated a Buy rating and $28 price target on shares.

H.C. Wainwright

Patrick Trucchio

Buy

maintain

$12

2025-06-26

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$12

2025-06-26

maintain

Buy

Reason

H.C. Wainwright analyst Patrick Trucchio says the selloff in shares of Altimmune on the IMPACT readout appears overdone. The company announced positive topline data from the 24-week Phase 2b IMPACT trial evaluating pemvidutide in metabolic dysfunction-associated steatohepatitis, the analyst tells investors in a research note. While fibrosis improvement without worsening of MASH was observed in 31.8% and 34.5% of patients in the 1.2 mg and 1.8 mg arms, respectively, compared to 25.9% for placebo, these differences did not reach statistical significance, adds H.C. Wainwright. However, the firm says AI-based fibrosis reads and non-invasive tests showed significant improvements, "reinforcing evidence of anti-fibrotic activity." Wainwright believes these data support advancement to Phase 3 and strengthen the case for pemvidutide as a potential best-in-class therapy. It reiterates a Buy rating on Altimmune with a $12 price target. The stock in midday trading is down 55%, or $4.21, to $3.51.

B. Riley

Buy

maintain

$20

2025-06-26

Reason

B. Riley

Price Target

$20

2025-06-26

maintain

Buy

Reason

B. Riley reiterated a Buy rating and $20 price target on Altimmune, adding that it is putting its price target under review after the company announced results from IMPACT Phase 2b trial of pemvidutide. The unusually high placebo response on the key fibrosis improvement endpoint paints a perception of mixed results, driving intraday equity weakness which the firm now views as overdone, the analyst tells investors in a research note. The firm added that biopsy variability overshadows the treatment's anti-MASH efficacy and tolerability.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$12

2025-04-03

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$12

2025-04-03

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Altimmune Inc (ALT.O) is -2.61, compared to its 5-year average forward P/E of -5.29. For a more detailed relative valuation and DCF analysis to assess Altimmune Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.29

Current PE

-2.61

Overvalued PE

-0.75

Undervalued PE

-9.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.00

Current EV/EBITDA

-1.38

Overvalued EV/EBITDA

-0.31

Undervalued EV/EBITDA

-5.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

18316.26

Current PS

91364.62

Overvalued PS

63797.42

Undervalued PS

-27164.90

Financials

Annual

Quarterly

FY2025Q1

YoY :

0.00%

5.00K

Total Revenue

FY2025Q1

YoY :

-18.58%

-21.82M

Operating Profit

FY2025Q1

YoY :

-19.75%

-19.58M

Net Income after Tax

FY2025Q1

YoY :

-23.53%

-0.26

EPS - Diluted

FY2025Q1

YoY :

+2.95%

-16.84M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+2163.44%

-401.66K

FCF Margin - %

FY2025Q1

YoY :

-19.75%

-391.50K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

57.8K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

57.8K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ALT News & Events

Events Timeline

2025-07-09 (ET)

2025-07-09

07:32:36

Altimmune enrolls first patient in Restore Phase 2 trial

2025-06-26 (ET)

2025-06-26

13:00:58

Altimmune's Pemvi hits MASH goal, shows broad potential, says Stifel

2025-06-26

07:07:02

Altimmune announces results from IMPACT Phase 2b trial of pemvidutide

News

7.0

02:00 AMGlobenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

7.0

07-28Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

7.0

07-27PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

People Also Watch

FAQ

What is Altimmune Inc (ALT) stock price today?

The current price of ALT is 3.61 USD — it has decreased -2.17 % in the last trading day.

ALT

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ALT News & Events

Events Timeline

News

People Also Watch

FAQ

What is Altimmune Inc (ALT) stock price today?

What is Altimmune Inc (ALT)'s business?

What is the price predicton of ALT Stock?

What is Altimmune Inc (ALT)'s revenue for the last quarter?

What is Altimmune Inc (ALT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Altimmune Inc (ALT)'s fundamentals?

How many employees does Altimmune Inc (ALT). have?

What is Altimmune Inc (ALT) market cap?